16^th Asia Pacific Oncologists Annual Meeting May 13-14, 2019 Singapore

A Guillaume Pollet is a Specialized Breast Cancer Surgeon with Expertise in Oncoplasty and Global Care (Oncofertility) and Former G&O. His professional activity disrupts the conventional treatment after being educated in the Institut Curie, Paris, one of the most prestigious, innovative and precursor Cancer Center in the world. He is currently an Executive MBA at INSEAD Business School, Singapore.

Innovation? It's not that we need new ideas, but we must stop having old ideas-Edwin Land, inventor of the Polaroid. The medical world is facing a crucial period. The increase in the world population and its aging will generate a massive influx of patients. Cancer is one of the leading causes of death in the world. Access and reimbursement of treatments, as well as associated care, are costly priorities. No country in the world will be able to pay these costs if nothing changes. The current model of care must be redesigned. The concept of real-world evidence allows for a new form of scientific validation, associated with the standard of reference of randomized clinical trials, allowing the use of new treatments. Innovation in the detection and treatment of cancers affect all stages. The arrival of new players (start-ups, institutions, companies) and new technologies (AI, digital health, VR, blockchain, etc.) brings a different vision. The different contexts of the actors make it possible to accelerate this evolution. To be effective, it must be accompanied by the regulators, with a change of policy centered on a treatment of great value and responsible care. Expansion of insurance coverage and lower prices will not be enough. This requires that traditional actors adapt, relearn their job by integrating these advances. The range of possibilities is vast, the goals can be achieved if an environment works for everyone. Innovations are a catalyst for economic progress and social transformation if properly integrated.

Neeraj Jain is Associate Professor in radiation oncology at Sri Guru Ram Das University of Health Sciences Amritsar. He is eminent Radiation Oncologist and participated in numerous national and international conferences and presented papers. He is Senior Vice President of North Zone Association of Radiation Oncologists of India and Vice Chairman of Indian College of Radiation Oncologists (ICRO).

India is a developing country. The present population is 1.35 billion. 1.4 million new cancer patients are diagnosed every year. A total of 2.25 million cases are prevalent at a given time. Mortality from cancer is as high as 1.2 million. Cervix and breast are leading cancers among females and head neck and lung are leading cancers among males. Due to poverty and illustration there is lack of awareness which leads to presentation at advanced or metastatic stage. The treatment in most of cases is palliative though now the awareness about cancer has increased and urban population is very conscious about the disease. Financial constraints are other issue for a radical and effective treatment. Lack of health insurance leads to a financial burden on effected family and despite being in a curable stage the patient fails to get required treatment. Central and state governments have started funding programs for diagnosis and treatment, but still costlier target therapies are beyond reach of majority of the patients. More and more funds are being allocated under National Cancer Control Program with sole aim of early detection and cure. Pharma companies are also running patient assistance programs and costly medicines are given as free cycles after patient purchases initial cycles. So, over all scenarios is positive.

Nitosh Kumar Brahma a life Fellow of The Institution of Engineers, India. He is actively engaged as Convener of WBSC/IEI, Chemical Engineering Division and as Visiting Professor of Institute of Genetic Engineering (IGE) Badu, Madhamgram. He completed his double Graduation with Distinction; BSc ÇU, B Tech, M Tech, TUB and Doctoral work in Max-Planck Germany 1968-1986. He published more than 100 articles related to Genetic Engineering, Chemical and Bio-Chemical Process Technology. He is the author of three books entitled Introduction to Chemical Science and Engineering, Molecular and Engineering Concepts of Micro-Biology and Bacterial adherence.

Benign tumors that are not identified as malignant and the malignant tumor which is identified as cancer must follow two different human physiological and immunological consequences. We all carry cancer cells and or generate cancer cells continuously during our growths and metabolic processes and by environmental impacts, like temperature, humidity, smokes, dust and UV of sunrays. The concept of BNT (Bionanotube of Escherichia coli K-12) is one such concept to optimize the delivery system of chemotherapeutic drugs and to sustain the body immune system/bidirectional immune response (i.e. to kill cancer malignant cells through chemotherapeutic drugs, immobilized in BNT and at the same time helps to normalize the body immune system, since BNT is genetically engineered E. coli cell, there extracted surface antigen fimbriae (pili), are the expressed cloned gene of cancer cell. BNT carrying cancer chemotherapeutic drug immobilized, is specific to the cancer cell and the necessitate body immune response responsible to sustain the body immune response. The main danger in chemotherapy is the damage of patient's immune system during and after administration, responsible to prevent the growth of opportunistic bacterial growths, increasing in case of immune suppression, susceptible to the body. BNT has initiated the concept for anticancer drug from the studies of anti-adherent activities of microbes in Balb/C mice to prevent fatal diarrhea. The immune response in this case was unique to observe the difference in mortality of mice against inoculums of donor fatal diarrhea causing bacteria and a group with BNT injected peritoneal survived against fatal diarrhea causing bacteria infected to mice and increased up to 10 8 ells/0.2 ml.